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Type 1 diabetes (T1D) is a metabolic disease caused by the autoimmune destruction of 
insulin-producing β-cells. With its incidence increasing worldwide, to find a safe approach 
to permanently cease autoimmunity and allow β-cell recovery has become vital. Relying 
on the inherent ability of apoptotic cells to induce immunological tolerance, we demon-
strated that liposomes mimicking apoptotic β-cells arrested autoimmunity to β-cells and 
prevented experimental T1D through tolerogenic dendritic cell (DC) generation. These 
liposomes contained phosphatidylserine (PS)—the main signal of the apoptotic cell mem-
brane—and β-cell autoantigens. To move toward a clinical application, PS-liposomes 
with optimum size and composition for phagocytosis were loaded with human insulin 
peptides and tested on DCs from patients with T1D and control age-related subjects. 
PS accelerated phagocytosis of liposomes with a dynamic typical of apoptotic cell 
clearance, preserving DCs viability. After PS-liposomes phagocytosis, the expression 
pattern of molecules involved in efferocytosis, antigen presentation, immunoregulation, 
and activation in DCs concurred with a tolerogenic functionality, both in patients and 
control subjects. Furthermore, DCs exposed to PS-liposomes displayed decreased ability 
to stimulate autologous T cell proliferation. Moreover, transcriptional changes in DCs from 
patients with T1D after PS-liposomes phagocytosis pointed to an immunoregulatory pro-
life. Bioinformatics analysis showed 233 differentially expressed genes. Genes involved 
in antigen presentation were downregulated, whereas genes pertaining to tolerogenic/
anti-inflammatory pathways were mostly upregulated. In conclusion, PS-liposomes 
phagocytosis mimics efferocytosis and leads to phenotypic and functional changes in 
human DCs, which are accountable for tolerance induction. The herein reported results 
reinforce the potential of this novel immunotherapy to re-establish immunological toler-
ance, opening the door to new therapeutic approaches in the field of autoimmunity.
Keywords: immunotherapy, autoimmunity, human type 1 diabetes, liposomes, tolerance, dendritic cells
Abbreviations: DC, dendritic cell; PS, phosphatidylserine; T1D, type 1 diabetes.
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inTrODUcTiOn
Type 1 diabetes (T1D) mellitus is a metabolic disease caused by 
loss of tolerance to self and consequent autoimmune destruction 
of insulin-producing pancreatic β-cells (1). When β-cell mass 
decreases significantly, the individual’s endogenous production 
of insulin is no longer able to meet metabolic demands, leading to 
overt hyperglycemia. Upon diagnosis, patients with T1D require 
exogenous insulin administration, and although this treatment 
has allowed them to survive, long-term complications due to gly-
cemic imbalances are bound to arise (2, 3). T1D usually appears 
during childhood or adolescence, and its incidence is increasing 
an average of 4% per year (4). Despite knowing that both genetic 
and environmental factors contribute to its development, trig-
gering events remain elusive. The autoimmune attack against 
β-cells is led by a mild leukocytic infiltrate—insulitis—consisting 
of dendritic cells (DCs), macrophages, T and B lymphocytes, and 
natural killer cells, which gradually advance through the islets 
(5). The first islet-infiltrating cells are DCs (6), which orchestrate 
the loss of tolerance to β-cell autoantigens, insulin being a key 
autoantigen in human T1D (7).
The first step to revert T1D would be to arrest the pathologi-
cal recognition of β-cell autoantigens. Many immunotherapies 
have prevented and even reverted T1D in animal models (8), but 
clinical trials have corroborated how challenging T1D preven-
tion and reversion is, and most of them have been unsuccessful 
(9). In this scenario, the development of new therapies to halt 
autoimmunity in T1D has become an urgent biomedical matter. 
An ideal immunotherapy should restore tolerance to β-cells, 
avoiding systemic side effects, and allow islet regeneration. One 
of the most efficient physiological mechanisms for inducing 
tolerance is apoptosis, a form of programmed cell death lack-
ing inflammation. The uptake of apoptotic cells by professional 
phagocytes such as macrophages and immature DCs (iDCs) is 
named efferocytosis (10). The exposure of “eat-me” signals on 
the apoptotic cell surface is what promotes their specific recogni-
tion and phagocytosis. Phosphatidylserine (PS), a phospholipid 
usually kept in the inner leaflet of the plasma membrane, is a 
relevant signal for efferocytosis. This molecule is recognized by 
multiple distinct receptors on antigen presenting cells, including 
members of the TIM family, Stabilin-2, integrins, CD36, CD68, 
among others, as well as by soluble receptors that in turn bind to 
membrane receptors (11). After the capture, the apoptotic cell 
is processed, thus prompting the release of anti-inflammatory 
signals and presentation of autoantigens in a tolerogenic manner 
by DCs (12). Failure of this mechanism, owing to an increase of 
apoptotic β-cells or defects in efferocytosis, contributes to the loss 
of tolerance to self in the context of T1D (13).
Our group demonstrated that DCs acquired a tolerogenic phe-
notype and functionality after engulfment of apoptotic β-cells, 
and that they prevented T1D when transferred to non-obese dia-
betic (NOD) mice (14, 15). However, since finding a substantial 
source of autologous apoptotic β-cells for T1D immunotherapy 
would be impossible, we conceived an immunotherapy based 
on biomimicry that consisted of liposomes—phospholipid 
bilayer vesicles—displaying PS in their surface and containing 
autoantigenic peptides, thus resembling apoptotic cells. Indeed, 
apoptotic mimicry performed by PS-liposomes successfully 
restored tolerance to β-cells in experimental autoimmune diabe-
tes, preventing disease development and decreasing the severity 
of insulitis (16). Moreover, by only replacing the autoantigenic 
peptide encapsulated within PS-liposomes, we confirmed the 
potential of this immunotherapy to prevent and ameliorate 
experimental autoimmune encephalomyelitis, the experimental 
model of multiple sclerosis (17). In both cases, we demonstrated 
that phagocytosis of autoantigen-loaded PS-liposomes induced 
a tolerogenic phenotype and functionality in DCs, expansion of 
regulatory T  cells and release of anti-inflammatory mediators 
that are responsible for arresting the autoimmune attack to 
target cells. Therefore, PS-liposomes could constitute a platform 
serving as a physiological and safe strategy to restore peripheral 
tolerance in antigen-specific autoimmune diseases. Liposomes, 
already used clinically as drugs deliverers for antitumor drugs 
and as vaccines (18), have the advantage of being safe and 
biocompatible, customizable, easily large-scale produced, and 
standardizable.
Aiming for the clinical potential of this strategy, we have 
encapsulated human insulin peptides to assess the effect of 
PS-liposomes in human DCs from patients with T1D and 
control subjects in vitro. We herein report that PS-liposomes are 
efficiently captured by human DCs, thus eliciting transcriptomic, 
phenotypic, and functional changes that point to tolerogenic 
potential. This immunotherapy constitutes a promising strategy 
to arrest autoimmune aggression in human T1D, benefiting from 
the co-delivery of tolerogenic signals and β-cell autoantigens.
MaTerials anD MeThODs
Patients
Patients with T1D (n = 34) and control subjects (n = 24) were 
included in this study. All patients with diabetes fulfilled the clas-
sification criteria for T1D. Inclusion criteria were 18–55 years of 
age, a body mass index (BMI) between 18.5 and 30 kg/m2 and, 
for patients with T1D, an evolution of the disease longer than 
6 months. Exclusion criteria were: being under immunosuppres-
sive or anti-inflammatory treatment, or undergoing pregnancy or 
breastfeeding. For the RNA-sequencing (RNA-seq) experiment, 
we selected 8 patients of the 34 that participated in the study, 
but BMI was limited to a maximum of 24.9 kg/m2, duration of 
the disease was restricted to a maximum of 5 years (in order to 
minimize the effect that long-term hyperglycemia could have 
on genetic and/or epigenetic profiles) and the presence of other 
chronic diseases became an exclusion criterion. All study partici-
pants gave informed consent, and the study was approved by the 
Committee on the Ethics of Research of the Germans Trias i Pujol 
Research Institute and Hospital.
cell separation and generation of Dcs
Peripheral blood mononuclear cells (PBMCs) were obtained 
from 50 ml blood samples of control subjects and patients with 
T1D by means of Ficoll Paque (GE Healthcare, Marlborough, 
MA, USA) density gradient centrifugation. Monocytes were 
further magnetically isolated using the EasySep Human CD14 
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Positive Selection Kit (STEMCELL Technologies, Vancouver, BC, 
Canada) following the manufacturer’s instructions. Once CD14 
purity in the positively selected fraction was >70%, monocytes 
were cultured at a concentration of 106 cells/ml in X-VIVO 
15 media (Lonza, Basel, Switzerland), supplemented with 2% 
male AB human serum (Biowest, Nuaillé, France), 100 IU/ml 
penicillin (Normon SA, Madrid, Spain), 100 µg/ml streptomycin 
(Laboratorio Reig Jofré, Sant Joan Despí, Spain), and 1,000 IU/
ml IL-4 and 1,000  IU/ml GM-CSF (Prospec, Rehovot, Israel) 
to obtain monocyte-derived DCs. After 6  days of culture, DC 
differentiation yield was assessed by CD11c-APC staining 
(Immunotools, Friesoythe, Germany) and cell viability was 
determined by annexin V-PE (Immunotools) and 7aad staining 
(BD Biosciences, San Jose, CA, USA) using flow cytometry (FACS 
Canto II, BD Biosciences). The negatively selected fraction of 
PBMCs was cryopreserved in Fetal Bovine Serum (ThermoFisher 
Scientific, Waltham, MA, USA) with 10% dimethylsulfoxide 
(Sigma-Aldrich, Saint Louis, MO, USA) and stored for later use.
Peptide selection and Preparation of 
liposomes
Thinking in a future clinical application of liposomes, the two 
chains of insulin were selected to be encapsulated separately in 
order to avoid possible biological effects of insulin. A and B chains 
of insulin contain well-known β-cell specific target epitopes in 
human T1D (19). Peptide A corresponds to the whole human 
insulin A chain (21 aa, N-start-GIVEQCCTSICSLYQLENYCN-
C-end), and peptide B is the whole human insulin B chain (30 aa, 
N-start-FVNQHLCGSHLVEALYLVCGERGFFYTPKT-C-end) 
(Genosphere Biotechnologies, Paris, France). Peptides were >95% 
pure and trifluoroacetic acid was removed. Liposomes consisted 
of 1,2-dioleoyl-sn-glycero-3-phospho-l-serine (sodium salt) 
(Lipoid, Steinhausen, Switzerland), 1,2-didodecanoyl-sn-glycero-
3-phosphocholine (Lipoid), and cholesterol (Sigma-Aldrich). 
Liposomes were prepared using the thin film hydration method 
from a lipid mixture of 1,2-dioleoyl-sn-glycero-3-phospho-
l-serine, 1,2-didodecanoyl-sn-glycero-3-phosphocholine and 
cholesterol at 1:1:1.33  molar ratio, respectively, as described 
(20). Liposomes without PS were generated as controls with 
1,2-didodecanoyl-sn-glycero-3-phosphocholine and cholesterol 
at 1:1  molar ratio. All liposomes were produced under sterile 
conditions and at a final concentration of 30 mM. Lipids were 
dissolved in chloroform and the solvent was removed by evapora-
tion under vacuum and nitrogen. The lipids were hydrated with 
the appropriate buffer (phosphate buffered saline or 0.5 mg/ml 
solution of peptide A or peptide B) and the liposomes obtained 
were homogenized to 1  µm by means of an extruder (Lipex 
Biomembranes Inc., Vancouver, BC, Canada). Peptide encapsula-
tion efficiencies were calculated according to the equation: encap-
sulation efficiency (%) =  [(Cpeptide,total-Cpeptide,out)/Cpeptide,total] ×100, 
where Cpeptide,total is the initial peptide A or peptide B concentration 
and Cpeptide,out is the concentration of non-encapsulated peptide. 
To measure the Cpeptide,out, liposome suspensions were centrifuged 
at 110,000 g at 10°C for 30 min. The concentration of non-encap-
sulated peptide was assessed in supernatants by PIERCE BCA 
protein assay kit (ThermoFisher Scientific). In addition to PS-rich 
liposomes loaded with insulin peptides [PSA-liposomes (n = 3) 
and PSB-liposomes (n = 3) encapsulating peptide A or peptide B, 
respectively], fluorescent-labeled liposomes with PS (empty fluo-
rescent PS-liposomes, n = 4) and without PS (empty fluorescent 
PC-liposomes, n = 4) were also prepared using lipid-conjugated 
fluorescent dye Oregon Green 488 1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine (Invitrogen, Carlsbad, CA, 
USA) and following the aforementioned methodology. Particle 
size distributions and stability—expressed as zeta potential 
(ζ)—were measured by dynamic light scattering using Malvern 
Zetasizer (Malvern Instruments, Malvern, UK) in undiluted 
samples. Liposome morphology and lamellarity were examined 
by cryogenic transmission electron microscopy (cryo-TEM) in a 
JEOL-JEM 1400 microscope (Jeol Ltd., Tokyo, Japan).
Phagocytosis assay
To assess whether DCs were able to phagocyte liposomes, DCs 
were co-cultured with 100 µM of empty fluorescent PS-liposomes 
(n =  5 for control subjects and n =  10 for patients with T1D) 
or empty fluorescent PC-liposomes (n =  6 for control subjects 
and n = 9 for patients with T1D) at 37°C from 5 min to 24 h. 
As control, the same assay was performed at 4°C to confirm that 
liposomes were captured by an active mechanism of phagocytosis. 
Cells were extensively washed in cold phosphate buffered saline 
to remove all liposomes attached to the cell membrane. Liposome 
uptake was determined by flow cytometry (FACSCanto II, BD 
Biosciences).
assessment of Dcs Phenotype after 
liposome Uptake
Although insulin chains were encapsulated separately, DCs 
were stimulated by a mixture of PSA-liposomes (50%) and PSB-
liposomes (50%), in order to assess the effect of the whole insulin 
molecule as autoantigen. Thus, DCs from control subjects (n ≥ 5) 
and patients with T1D (n ≥ 8) were co-cultured with 1 mM of 
liposomes (PSAB-DCs) for 24 h in the presence of 20 µg/ml human 
insulin (Sigma-Aldrich), and their viability and phenotype were 
analyzed by flow cytometry (FACSCanto II, BD Biosciences). The 
sample number stated (n) is referred to the minimum number 
of control subjects and patients included in each experiment. As 
controls, DCs were either cultured with 20 µg/ml human insulin 
(Sigma-Aldrich) to obtain iDCs or adding a cytokine cocktail 
(CC) consisting of tumor necrosis factor (TNF)α (1,000  IU/
ml, Immunotools), IL-1β (2,000  IU/ml, Immunotools) and 
Prostaglandin E2 (PGE2, 1 µM, Cayman Chemical, Ann Arbor, 
MI, USA) for 24  h to obtain mature DCs (mDC). Moreover, 
PSAB-DCs were cultured after phagocytosis with CC for 24 h in 
order to assess the response in front a pro-inflammatory stimulus 
(mPSAB-DCs). Phenotyping was performed as follows: DCs were 
stained with 7aad (BD Biosciences) and monoclonal antibodies 
to CD11c-APC, CD25-PE, CD86-FITC, HLA class I-FITC, 
HLA class II-FITC, CD14-PE and CD40-APC (Immunotools), 
CD36-APCCy7, TIM4-APC, αvβ5 integrin-PE, CD54-PECy7, 
TLR2-FITC, CXCR4-APCCy7, CCR2-APC, DC-SIGN-APC 
(Biolegend, San Diego, CA, USA) and CCR7-PECy7 (BD 
Biosciences). Corresponding fluorescence minus one staining 
was used as control. Data were analyzed using FlowJo software 
(Tree Star Inc., Ashland, OR, USA).
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T cell Proliferation assays
Autologous T lymphocyte proliferation (n = 12 for control sub-
jects and n ≥ 12 for patients with T1D) was assessed by exposing 
PBMCs to the different conditions of DCs used in this study. 
Briefly, PBMCs from the same donor were thawed and stained 
with 0.31  µM CellTrace Violet (21) (ThermoFisher Scientific) 
according to manufacturer’s instructions. The PBMCs were then 
co-cultured with iDCs, PSAB-DCs, mPSAB-DCs or mDCs at 
a 10:1 ratio (105 PBMCs:104 DCs). For each donor, 105 PBMCs 
were cultured in basal conditions as a negative control or with 
Phorbol 12-Myristate 13-Acetate (50 ng/ml, Sigma-Aldrich) and 
Ionomycin (500  ng/ml, Sigma-Aldrich) as a positive control. 
After 6 days of co-culture, proliferation was assessed in the dif-
ferent T  cell subsets with CD3-PE, CD4-APC and CD8-FITC 
staining (Immunotools) by flow cytometry (FACS LSR Fortessa, 
BD Biosciences). Data were analyzed using FlowJo software (Tree 
Star Inc.).
cytokine Production
The Human Th1/Th2/Th17 kit (CBA system; BD Biosciences) 
was used to assess cytokine production. Culture supernatants 
from DCs and from T cell proliferation assays (n ≥ 3 for control 
subjects and n ≥ 3 for patients with T1D) were collected and fro-
zen at −80°C until use. IL-2, IL-4, IL-6, IFN-γ, TNF, IL-17A, and 
IL-10 were measured. Data were analyzed using CBA software. 
The production of Human TGF-β1 by DCs after PSAB-liposome 
uptake was determined by ELISA (eBioscience, San Diego, CA, 
USA).
rna-seq of Dcs before and after 
liposome Phagocytosis
Dendritic cells obtained from patients with T1D (n =  8) were 
cultured in basal conditions (iDCs) or with 1  mM of PSA-
liposomes and PSB-liposomes (PSAB-DCs) at 37°C for 4 h. Cells 
were then harvested from culture wells using Accutase (eBiosci-
ence), and viability and DC purity were assessed with 7aad (BD 
Biosciences), annexin V-PE and CD11c-APC (Immunotools) 
staining by flow cytometry (FACS Canto II, BD Biosciences). 
Liposome capture control assays were performed for every sample 
(see above Phagocytosis Assay section) to confirm phagocytosis. 
Supernatant was removed and cell pellets were stored at  −80°C 
until use. RNA was extracted using RNeasy Micro Kit (QIAGEN, 
Hilden, Germany) and following manufacturer’s instructions. 
RNA purity, integrity and concentration were determined 
by NanoDrop (ND-1000 Spectrophotometer, ThermoFisher 
Scientific) and 2100 Bioanalyzer (Agilent Technologies Inc., 
Santa Clara, CA, USA). Afterward, 1 µg of total RNA was used to 
prepare RNA libraries following the instructions of the NebNext 
Ultra Directional RNA Library Prep Kit (New England Biolabs, 
Ipswich, MA, USA). Library quality controls were assessed using 
a TapeStation 2200 (Agilent High Sensitivity Screen Tape) and a 
narrow distribution with a peak size of approximately 300 bp was 
observed in all cases. Libraries were quantified by qPCR using a 
QC KAPA kit (Hoffman-LaRoche, Basel, Switzerland) sequenced 
in a NextSeq 500 genetic analyzer (SBS-based sequencing 
technology, Illumina, San Diego, CA, USA) in a run of 2 × 75 
cycles and a high output sequencing mode. Twenty million reads 
were obtained and analyzed for each sample. Fastq files coming 
from Illumina platform were merged and basic quality controls 
were performed with FASTQC and PRINSEQ tools. Paired-end 
(forward-reverse) sample merging was carried out with software 
CLCBio Genomics Workbench® version 8.5 (22), following the 
RNA-seq analysis pipeline found in CLCBio manuals. Read align-
ment and mapping steps to only gene regions were performed 
using CLCBio software against the human genome (Homo sapi-
ens GRCh38 assembly, at both gene- and transcript-level tracks). 
The same software, with default options, was used to normalize 
counts by applying standard “Reads Per Kilobase of transcript 
per Million reads mapped” method. The remaining steps of the 
analysis were carried out with scripts and pipelines implemented 
with R software (23). The selection of differentially expressed 
genes (DEGs) was performed using the linear model approach 
implemented in the limma Bioconductor package (24), with 
previous log2-transformation of the normalized data. Adjusted 
p values of ≤0.125, taking into account multiple testing with 
the False Discovery Rate method, were considered significant. 
Therefore, genes with a p value <0.0013 and Log2 of fold change 
>0.05 were considered upregulated, whereas those with Log2 of 
fold change <0.05 were considered downregulated. Experimental 
data have been uploaded into European Nucleotide Archive (EBI, 
https://www.ebi.ac.uk/ena; accession number: PRJEB22240). 
DEGs were categorized using Ingenuity Pathway Analysis 
Software (QIAGEN), Protein Analysis Through Evolutionary 
Relationships Classification System (25), REACTOME Pathway 
database (26) and Gene Ontology Biological Process database 
(27). Furthermore, R software (23) was used to generate a gene 
heatmap of DEGs.
Quantitative rT-Pcr
To validate transcriptome results, DCs obtained from patients 
with T1D (n ≥ 4) and control subjects (n ≥ 3) were cultured and 
pelleted in three conditions: iDCs, PSAB-DCs and mDCs. RNA 
was isolated using RNeasy Micro Kit (QIAGEN), and was reverse-
transcribed with a High Capacity cDNA Reverse Transcription 
Kit (ThermoFisher Scientific). cDNA synthesis reactions were 
carried out using random hexamers (0.5 mg/ml, BioTools, Valle 
de Tobalina, Madrid, Spain) and reverse transcriptase Moloney-
murine-Leukemia-virus (200  U/ml, Promega, Madison, WI, 
USA). Quantitative RT-PCR assays were performed with TaqMan 
universal assay (ThermoFisher Scientific) on a LightCycler® 480 
(Roche, Mannheim, Germany) using the following TaqMan 
assays: CYTH4 (Hs01047905_m1), GIMAP4 (Hs01032964_m1), 
HPGD (Hs00960590_m1), NFKB inhibitor alpha (NFKBIA) 
(Hs00153283_m1), PLAUR (Hs00958880_m1), TNFAIP3 
(Hs00234713_m1), tumor necrosis factor superfamily member 14 
(TNFSF14) (Hs00542477_m1), and VEGFA (Hs00900055_m1). 
Relative quantification was performed by normalizing the expres-
sion for each gene of interest to that of the housekeeping gene 
GAPDH (Hs02758991_g1), as described in the 2–ΔCt method (28).
statistical analysis
The statistical analysis was performed using Prism 7.0 software 
(GraphPad software Inc., San Diego, CA, USA). Analysis of 
Table 1 | Data from the control subjects and patients with T1D recruited for the 
study.
control subjects Patients with T1D p Value
N 24 34 —
Gender 11/24 (45.8%) Female 17/34 (50%) Female —
13/24 (54.2%) Male 17/34 (50%) Male
Age (years) 30.46 ± 8.18 32.54 ± 8.96 0.4301
BMI (kg/m2) 23.90 ± 2.87 23.80 ± 3.11 0.9075
Age at T1D diagnosis 
(years)
NA 20.79 ± 9.90 —
Duration of T1D (years) NA 11.75 ± 9.70 —
HbA1c (%) NA 7.66 ± 1.26 —
Data presented as mean ± SD; p value calculated from Mann–Whitney test.
T1D: type 1 diabetes; BMI, body mass index; NA, not applicable.
Table 2 | Data from the patients with T1D included in the RNA-seq experiment.
Patient number gender age (years) bMi (kg/m2) age at T1D diagnosis (years) Duration of T1D (years) hba1c (%)
1 Male 23 21.2 19 4 6.7
2 Female 28 24.4 23 5 6.5
3 Male 28 23.0 25 3 7.4
4 Female 33 21.4 33 0.5 5.9
5 Female 35 24.4 34 1 6.4
6 Female 32 18.6 31 0.5 5.9
7 Male 38 24.2 36 1 12.2
8 Male 21 23.0 16 5 7.9
Mean ± SD 29.75 ± 5.85 22.50 ± 2.00 27.13 ± 7.43 2.50 ± 1.98 7.36 ± 2.07
Data presented as mean ± SD.
T1D, type 1 diabetes; BMI, body mass index.
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variance (ANOVA) was used for comparisons with several 
factors. For comparisons of unpaired data, a non-parametric 
Mann-Whitney test was used; for paired comparisons, a non-
parametric Wilcoxon test was used. A p value ≤ 0.05 was con-
sidered significant.
resUlTs
Patients with T1D and control subjects 
Display similar Features
Thirty-four patients with T1D (50% female, 50% male) from the 
Germans Trias i Pujol Hospital and 24 control subjects (45.8% 
female, 54.2% male) met the inclusion and exclusion criteria 
and were included in the study (Table 1). Age of control subjects 
was 30.46 ± 8.18 years (mean ± SD), while that of patients with 
T1D was 32.54 ± 8.96 years; BMI was 23.90 ± 2.87 kg/m2 and 
23.80 ±  3.11  kg/m2, respectively. Patients with T1D had been 
diagnosed at 20.79 ±  9.90  years, had a duration of disease of 
11.75 ± 9.70 years, and a hemoglobin A1c level of 7.66 ± 1.26%. 
Control subjects did not significantly differ from patients with 
T1D in terms of age or BMI. Within the 34 patients, we selected 
8 for the RNA-seq analysis, 50% female and 50% male, with a 
more stringent inclusion and exclusion criteria. Their age was 
29.75 ± 5.85 years and their BMI was 22.50 ± 2.00 kg/m2. They 
had been diagnosed with T1D at 27.13  ±  7.43  years, had a 
duration of the disease of 2.50 ±  1.98 years and a hemoglobin 
A1c level of 7.36 ± 2.07%. Specific information on each subject 
can be found in Table 2.
Dc Differentiation efficiency is similar in 
Patients with T1D and control subjects
Monocytes were isolated magnetically from PBMCs. The yield 
of monocyte isolation—calculated as the percentage of the 
absolute number of CD14+ cells in the positively isolated frac-
tion related to the absolute number of CD14+ cells in PBMCs—
was 54.95  ±  24.97% (mean  ±  SD) for control subjects and 
56.62 ± 18.12% for patients with T1D. The percentage of purity 
of CD14+ cells in the isolated fraction was 80.59 ±  10.18% for 
control subjects and 79.33 ± 7.56% for patients, and viability was 
95.06 ± 4.14 and 94.92 ± 3.60%, respectively. The efficiency of 
differentiation to DCs at day 6 was 87.96 ±  6.61% for control 
subjects and 86.92 ± 6.86% for patients. No statistically signifi-
cant differences were found when comparing these parameters 
between both groups. Data are detailed in Table 3.
Ps-liposomes show Multivesicular 
Vesicle Morphology and encapsulate 
insulin Peptides
Liposomes were characterized in terms of diameter, polydis-
persity index (PdI), surface charge (ζ-potential) and efficiency 
of peptide encapsulation (Table  4). All liposomes had a final 
lipid concentration of 30  mM. All liposomes were large to 
guarantee efficient phagocytosis, displaying a diameter supe-
rior to 690 nm. The presence of PS molecules in liposomes was 
confirmed by the negative charge measured at the liposome 
surface by ζ-potential (−38 mV). Regarding specific features 
of PSA-liposomes (n = 3), the mean diameter was 690 ± 29 nm 
(mean ± SD), the PdI was 0.40 ± 0.28 and the ζ-potential was 
−38.57 ± 6.76 mV. The mean of peptide A (human insulin A 
chain) encapsulation efficiency was 39.74 ± 22.10%. As for PSB-
liposomes (n = 3), they had a mean diameter of 788 ± 264 nm, 
the PdI was 0.52 ± 0.42 and the ζ-potential was −37.50 ± 7.16 
mV, and the mean of peptide B (human insulin B chain) encap-
sulation efficiency was 93.19 ±  0.92%. Differences in peptide 
encapsulation efficiency (PSA vs. PSB) are due to amino acid 
composition and different solubility of insulin chains A (21 
FigUre 1 | PS-liposomes display multivesicular and multilamellar morphology. Cryogenic transmission electron microscopy images of (a) PSA-liposomes (left) and 
(b) PSB-liposomes (right). Bar = 0.2 μm.
Table 4 | Features of the liposomes used in the study.
liposome type Diameter (nm) Polydispersity index ζ-potential (mV) encapsulation efficiency (%)
PSA-liposomes 690 ± 29 0.40 ± 0.28 −38.57 ± 6.76 39.74 ± 22.10
PSB-liposomes 788 ± 264 0.52 ± 0.42 −37.50 ± 7.16 93.19 ± 0.92
Fluorescent PS-liposomes 836 ± 217 0.32 ± 0.06 −38.90 ± 2.52 (empty)
Fluorescent PC-liposomes 1665 ± 488 0.32 ± 0.09 −7.60 ± 2.68 (empty)
Data presented as mean ± SD.
Table 3 | Data from monocyte’s isolation and dendritic cell differentiation.
Yield  
(day 1, %)
Purity  
(day 1, %)
Viability  
(day 1, %)
Differentiation 
efficiency  
(day 6, %)
Control 
subjects
54.95 ± 24.97 80.59 ± 10.18 95.06 ± 4.14 87.96 ± 6.61
Patients 56.62 ± 18.12 79.33 ± 7.56 94.92 ± 3.60 86.92 ± 6.86
p Value 0.3789 0.2286 0.3664 0.5766
Yield: % of the absolute number of CD14+ cells in the positively isolated fraction related 
to the absolute number of CD14+ cells in PBMCs. Purity: % of CD14+ cells in the isolated 
fraction. Viability: % of Annexin V–7aad– cells. Differentiation efficiency: % of CD11c+ cells. 
Data presented as mean ± SD; p value calculated from Mann–Whitney test.
T1D, type 1 diabetes.
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human Dcs Display Optimal Kinetics of 
Ps-liposomes Phagocytosis without 
affecting Viability
A time course analysis was performed to determine PS-liposomes 
uptake kinetics (Figure 2A, upper left panel). The capture of empty 
fluorescent PS-liposomes by DCs was significantly higher at 37°C 
when compared to 4°C (p < 0.001), coming from either control 
subjects (n = 5) or patients (n = 10). This result is immunologi-
cally crucial and demonstrates that DCs engulf liposomes by an 
active mechanism of phagocytosis. PS-liposomes uptake kinetics 
were identical between control subjects and patients with T1D.
To indirectly assess the role of PS in phagocytosis, the 
same analysis was performed replacing PS-liposomes with 
PC-liposomes (Figure 2A, lower left panel). The percentages of 
empty PC-liposomes phagocytosis by DCs from control subjects 
(n =  6) and patients (n =  9) were significantly higher at 37°C 
when compared to 4°C starting at 2 h (p < 0.0001). The kinetics of 
the capture did not differ between control subjects and patients. 
When comparing uptake kinetics of PS- and PC-liposomes 
(Figure S1 in Supplementary Material), statistically significant dif-
ferences were found, as expected. The presence of PS significantly 
accelerated phagocytosis in the first 2 h of co-culture (p < 0.05) 
both in control subjects and patients. In preliminary experiments, 
each type of liposome was tested in several sizes (diameter range 
505–2,138  nm), and similar kinetics of capture were observed, 
aa) and B (30 aa) in phosphate buffered saline media. B chain 
is more positively charged than A chain at neutral pH, result-
ing in a higher encapsulation efficiency in negatively charged 
liposomes. PSA-liposomes and PSB-liposomes presented 
multivesicular vesicle morphology when cryo-TEM analysis 
was performed (Figure 1).
Fluorescent-labeled PS-liposomes (n =  4) showed a diam-
eter of 836 ±  217  nm, a PdI of 0.32 ±  0.06 and a ζ-potential 
of −38.90 ±  2.52 mV. Their PS-free counterparts, fluorescent 
PC-liposomes (n = 4), had a diameter of 1665 ± 488 nm, a PdI 
of 0.32 ± 0.09 and a ζ-potential of −7.60 ± 2.68 mV (Table 4).
FigUre 2 | Liposomes are efficiently phagocyted by dendritic cells (DCs) and preserve a high viability. (a) Uptake of liposomes fluorescently labeled with 
lipid-conjugated fluorescent dye Oregon Green 488 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine by DCs. Upper panel: time course of the capture of 
fluorescently-labeled PS-liposomes by DCs obtained from control subjects (white circles, n = 5) and patients with type 1 diabetes (T1D) (black circles, n = 10) at  
37°C (continuous line) and at 4°C (discontinuous line). Results are mean ± SEM. Comparisons between phagocytosis by control subjects DCs at 37 and 4°C 
showed significant differences [++++p < 0.0001, two-way analysis of variance (ANOVA)]; also, significant differences were found when comparing phagocytosis in 
patients with T1D at 37 and 4°C (***p < 0.001, ****p < 0.0001, Two-way ANOVA). No differences were found when comparing PS-liposomes uptake by DCs from 
control subjects and patients with T1D (Two-way ANOVA). Lower panel: time course of the capture of fluorescently-labeled PC-liposomes by DCs obtained from 
control subjects (white squares, n = 6) and patients with T1D (black squares, n = 9) at 37°C (continuous line) and at 4°C (discontinuous line). Results are 
mean ± SEM. Comparisons between phagocytosis by control subjects DCs at 37 and 4°C showed significant differences (++++p < 0.0001, Two-way ANOVA); also, 
significant differences were found when comparing phagocytosis in patients with T1D at 37 and 4°C (**p < 0.01, ****p < 0.0001, Two-way ANOVA). No differences 
were found when comparing PC-liposomes uptake by DCs from control subjects and patients with T1D (Two-way ANOVA). (b) Viability of DCs from control subjects 
(upper panel, white symbols, n ≥ 6) and patients with T1D (lower panel, black symbols, n ≥ 6) assessed by annexin V and 7aad staining. Triangles represent 
immature DCs (iDCs), circles represent iDCs cultured with PSA-liposomes and PSB-liposomes (PSAB-DCs), squares represent mature PSAB-DCs (mPSAB-DCs) 
and upside-down triangles represent mature DCs (mDCs). MDCs were induced by culture with cytokine cocktail.
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independently of liposome size (Figure S2 in Supplementary 
Material), thus confirming that PS is the key factor in accelerating 
phagocytosis.
The viability of the different conditions of DCs (iDCs, PSAB-
DCs, mPSAB-DCs, and mDCs) was assessed to determine 
liposome toxicity. The mean viability for each condition was 
always >90%, both in DCs obtained from control subjects (n ≥ 6) 
(Figure 2B, upper right panel), and patients with T1D (n ≥ 6) 
(Figure 2B, lower right panel).
Ps-liposomes Uptake regulates the 
Phenotypic Maturation of human Dcs
Changes in DCs phenotype were determined in control subjects 
(n ≥ 5) and patients with T1D (n ≥ 8). The membrane molecules 
assessed were: PS-receptors (CD36, TIM4, and αvβ5 integrin), 
antigen-presentation molecules (HLA-ABC and HLA-DR), 
adhesion molecules (CD54), costimulation molecules (CD40 
and CD86), activation molecules (CD25), chemokine receptors 
(CCR7, CCR2, and CXCR4), and pattern recognition receptors 
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(TLR2, CD14, and DC-SIGN). Figure 3 shows the relative Median 
of Fluorescence Intensity referred to mDCs.
PS-receptors CD36, TIM4 and αvβ5 integrin were expressed 
in iDCs. After liposome uptake, PSAB-DCs from patients 
decreased CD36 expression (p <  0.05) and upregulated TIM4 
expression (p <  0.05) in comparison to iDCs, but PSAB-DCs 
presented a higher expression of CD36 and TIM4 than mDCs 
from control subjects and patients (p < 0.05). Moreover, PSAB-
DCs from patients had increased levels of TIM4 in comparison 
to PSAB-DCs from control subjects (p < 0.05). The expression of 
αvβ5 integrin was higher in PSAB-DCs than in mDCs in patients 
(p < 0.05). As expected, CD36 and TIM4 were downmodulated in 
mDCs (p < 0.05), and αvβ5 integrin showed the same tendency.
Regarding HLA molecules, HLA-ABC was expressed similarly 
in iDCs and mDCs from both groups, and decreased in PSAB-
DCs from patients after liposome capture (p < 0.05) —and con-
trol subjects displayed the same tendency. Concerning HLA-DR, 
iDCs showed a lower expression of this marker when compared 
to mDCs (p < 0.001). After liposome phagocytosis (PSAB-DCs), 
the low HLA-DR levels were preserved. As for the expression of 
adhesion molecule CD54, it was lower in iDCs from patients in 
comparison to mDCs (p < 0.05), and control subjects displayed 
the same tendency. After liposome uptake, no changes in CD54 
expression were observed in PSAB-DCs when compared to iDCs, 
but mDCs displayed increased levels of CD54 in comparison 
to PSAB-DCs (p <  0.05). The expression of CD54 was higher 
in mPSAB-DCs exposed to a maturation stimulus despite the 
uptake of liposomes (p < 0.05).
Expression of costimulatory molecules CD40 and CD86 was 
lower in iDCs than in mDCs (p < 0.01). Liposome phagocytosis 
did not increase the expression of these molecules in PSAB-DCs. 
Moreover, PSAB-DCs presented lower levels of these markers 
when compared to mDCs (p < 0.0001), and even when exposed 
to pro-inflammatory stimulus (mPSAB-DCs) in comparison to 
mDCs (p < 0.05). Regarding the expression of activation marker 
CD25, it was lower in iDCs when compared to mDCs (p < 0.0001). 
Upregulation of CD25 was observed after liposome uptake 
in PSAB-DCs from control subjects (p <  0.01), but remained 
unaltered in patients. PSAB-DCs from both groups presented 
CD25 downmodulated when compared to mDCs (p <  0.001). 
Furthermore, DCs loaded with liposomes and exposed to pro-
inflammatory stimulus (mPSAB-DCs) displayed lower levels of 
CD25 than mDCs in patients with T1D (p < 0.01).
Chemokine receptors CCR7 and CCR2 were expressed in 
iDCs. After liposome capture, the expression of both molecules 
increased in patients with T1D (p < 0.05). CCR7 was upregulated 
in PSAB-DCs when compared to mDCs in patients (p < 0.05), 
and control subjects displayed the same tendency. CXCR4, 
overexpressed in mDCs in comparison to iDCs (p < 0.05), was 
maintained low after liposome engulfment (PSAB-DCs). The 
expression of CXCR4 was higher in DCs exposed to a matura-
tion stimulus despite the uptake of liposomes (mPSAB-DCs) 
(p < 0.05).
Pattern recognition receptors were assessed in DCs. TLR2 
expression was similar in all experimental conditions, despite 
showing a tendency to increase after liposome phagocytosis 
(PSAB-DCs) in patients. CD14 was similarly expressed in iDCs 
and mDCs, but liposome uptake and maturation stimulus induced 
downregulation of this marker (p < 0.05). DC-SIGN, expressed in 
iDCs, displayed a tendency to be downmodulated after liposome 
capture (PSAB-DCs), especially in controls, which was more 
marked after a pro-inflammatory stimulus. Nonetheless, this 
marker showed a tendency to remain higher in PSAB-DCs than 
in mDCs in patients.
In terms of cytokine secretion by DCs from patients (n ≥ 3) 
and control subjects (n ≥  3) (Figure  4), IL-6 was released in 
low amounts after liposome phagocytosis and, as expected, its 
secretion increased after maturation stimulus. TNF-α was not 
increased after liposome uptake and its secretion increased in 
pro-inflammatory conditions. Liposome engulfment maintained 
a high profile of TGF-β1 secretion both in control subjects and 
patients, and tended to decrease in mPSAB-DCs and mDCs, 
although non-significant. Regarding IL-10 production, PSAB-
DCs displayed a tendency to increase the secretion, although 
non-statistically significant, in patients with T1D. IL-2, IL-17A, 
and IFN-γ were not detected in any condition of the assay (data 
below the detection limit). IL-4 was not considered as it was used 
in culture media for DC differentiation.
Ps-liposomes Uptake impairs Dcs ability 
to stimulate autologous T cell 
Proliferation
DCs derived from patients with T1D (n ≥ 12) and control subjects 
(n = 12) induced similar levels of autologous T cell proliferation 
(Figure  5). As expected, CD4+ T  cell proliferation induced by 
mDCs was higher than proliferation induced by iDCs in both 
groups (p < 0.01). CD8+ T cell proliferation induced by mDCs 
was higher than proliferation induced by iDCs in control sub-
jects (p < 0.05), but not in patients. Importantly, the capture of 
PSAB-liposomes by iDCs did not increase autologous CD4+ and 
CD8+ T cell proliferation, both in patients and control subjects. 
Moreover, a significant decrease of CD8+ T  cell proliferation 
induced by PSAB-DCs from patients was observed after lipo-
some capture, when compared to iDCs (p < 0.01). This effect was 
reverted after DCs maturation.
In terms of cytokine production, PBMCs co-cultured with 
PSAB-DCs displayed a cytokine profile (IL-6 and IFN-γ) similar 
to iDCs (Figure  5). Interestingly, PBMCs showed a tendency 
to increase IFN-γ and IL-6 secretion when co-cultured with 
mPSAB-DCs or mDCs, respectively, only in patients with T1D. 
IL-2, IL-4, IL-10, IL-17A, and TNF-α were not detected in any 
condition of the assay (data below the detection limit).
Transcriptional changes in Dcs from 
Patients with T1D after Ps-liposomes 
Phagocytosis Point to an 
immunoregulatory Prolife
RNA-seq analysis was performed in DCs from 8 patients with 
T1D (Table 2) in order to identify transcriptional changes after 
the capture of PS-liposomes. Phagocytosis was verified by flow 
cytometry using fluorescent liposomes. After 4 h of co-culture, 
73.88 ± 11.57% (mean ± SD) of DCs were positive for fluorescent 
signal.
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FigUre 3 | Continued
FigUre 4 | The uptake of PSAB-liposomes by dendritic cells (DCs) does not alter cytokine profile. Concentration (pg/ml) of IL-6, TNF-α, TGF-β1, and IL-10 
secreted by DCs obtained from control subjects (white bars, n ≥ 3) and patients with type 1 diabetes (T1D) (black bars, n ≥ 3). Bars represent immature DCs (iDCs), 
iDCs after the capture of PSA-liposomes and PSB-liposomes (PSAB-DCs), mature PSAB-DCs (mPSAB-DCs), or mature DCs (mDCs). MDCs were induced by 
culture with cytokine cocktail. Data presented as mean ± SD. Significant differences were found when comparing the different conditions in the same group of 
subjects (*p < 0.05, Wilcoxon test), and differences were not found when comparing the same culture conditions between patients with T1D and control subjects 
(Mann–Whitney test).
FigUre 3 | Capture of PSA-liposomes and PSB-liposomes regulates dendritic cell (DCs) phenotype. Relative CD36, TIM4, Integrin αvβ5, HLA-ABC, HLA-DR, 
CD54, CD40, CD86, CD25, CCR7, CCR2, CXCR4, TLR2, CD14, and DC-SIGN membrane expression in DCs obtained from control subjects (white bars, n ≥ 5) 
and patients with type 1 diabetes (T1D) (black bars, n ≥ 8). Bars represent immature DCs (iDCs), iDCs after the capture of PSA-liposomes and PSB-liposomes 
(PSAB-DCs), mature PSAB-DCs (mPSAB-DCs), or mature DCs (mDCs), 24 h after culture. MDCs were induced by culture with cytokine cocktail. Data presented as 
mean ± SD of relative Median of Fluorescence Intensity (MFI), this being MFI of each culture condition referred to their respective mDCs control. Significant 
differences were found when comparing culture conditions in the same group of subjects (*p ≤ 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, Wilcoxon test), and 
when comparing the same culture conditions between patients with T1D and control subjects (+p < 0.05, Mann–Whitney test).
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Integrity of the isolated RNA material was assessed for each 
sample, being optimal for RNA-seq experiment: RIN 9.0 ± 0.56 
(mean ± SD). Bioinformatics analysis of the RNA-seq experiment 
revealed that only 233 of 22,711 genes detected were differen-
tially expressed between iDCs and PSAB-DCs (p value < 0.0013, 
adjusted p value < 0.1254). Of these 233 genes, 203 (87.12%) were 
downregulated and the remaining 30 (12.88%) were upregulated, 
and 224 corresponded to protein-coding genes. Despite the 
heterogeneous basal transcriptomics of DCs from eight patients, 
gene expression was clearly altered toward a similar profile 
after PS-liposomes phagocytosis (Figure S3 in Supplementary 
Material).
We analyzed several categories and molecules related to DC 
function (Table S1 in Supplementary Material). DEGs were mainly 
related to metabolism, gene expression, immunoregulation, sig-
nal transduction, molecule transport, post-translational protein 
modification, cytokine signaling, cell cycle, vesicle-mediated 
processes, DNA replication and repair, antigen processing and 
presentation, apoptosis, and cytoskeleton organization (Table 5). 
Due to the immunotherapeutic potential of PS-liposomes, DEGs 
involved in tolerance were analyzed in detail. DEGs linked to the 
immune system were primarily downregulated and involved in 
antigen processing and presentation (KBTBD6, BTK, CDC23, 
UBE2E3, CD1D), regulation of the immune response (DAPP1, 
FigUre 5 | Capture of PSA-liposomes and PSB-liposomes affects dendritic cells (DCs) functionality. (a) Relative autologous proliferation of CD3+CD4+ and 
CD3+CD8+ subsets induced by DCs obtained from control subjects (white bars, n = 12) and patients with type 1 diabetes (T1D) (black bars, n ≥ 12). Autologous 
peripheral blood mononuclear cells were stained with CellTrace Violet (CTV) and co-cultured at 1:10 ratio for 6 days with each condition of DCs, and proliferation 
was measured as the percentage of CTVlow cells. Bars represent immature DCs (iDCs), iDCs after the capture of PSA-liposomes and PSB-liposomes (PSAB-DCs), 
mature PSAB-DCs (mPSAB-DC), or mature DCs (mDCs). MDCs were induced by culture with cytokine cocktail. Data presented as mean ± SD of relative 
proliferation induction, this being the percentage of CTVlow cells in each co-culture condition referred to that of their respective mDCs control. Significant differences 
were found when comparing culture conditions in the same group of subjects (*p ≤ 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, Wilcoxon test), and differences 
were not found when comparing the same culture conditions between patients with T1D and control subjects (Mann-Whitney test). (b) IL-6 and IFN-γ secretion (pg/
ml) assessed in supernatants of autologous proliferation co-culture with cells from control subjects (white bars, n ≥ 3) and patients with T1D (black bars, n ≥ 3). Bars 
represent immature DCs (iDCs), iDCs after the capture of PSA-liposomes and PSB-liposomes (PSAB-DCs), mature PSAB-DCs (mPSAB-DC), or mature DCs 
(mDCs). MDCs were induced by culture with cytokine cocktail. Data presented as mean ± SD. No differences were found when comparing the different conditions 
in the same group of subjects (Wilcoxon test), or when comparing the same culture conditions between patients with T1D and control subjects (Mann–Whitney test).
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GIMAP4, SLAMF6) and cytokine signaling relevant in the inter-
action between T cells and DCs (SOCS2, TNFRSF11A). However, 
although very few genes were upregulated after PS-liposomes 
phagocytosis, these were related to the prevention of DC matura-
tion [TNFSF14, TNFAIP3, VEGFA, SHB, leukocyte associated 
immunoglobulin-like receptor 1 (LAIR1), NFKBIA]. Also, genes 
related to apoptosis were downregulated in DCs after liposome 
uptake (BLCAP, PMP22, LMNB1).
Validation by qRT-PCR of the selected gene targets (CYTH4, 
GIMAP4, HPGD, NFKBIA, PLAUR, TNFAIP3, TNFSF14, 
and VEGFA) confirmed the RNA-seq results, when tested in 
DCs from 10 patients with T1D (Figure 6). As expected, gene 
expression analysis in DCs from 9 control subjects showed the 
same pattern. Regarding mDCs—from 4 patients with T1D 
and 3 control subjects—we observed a seemingly different gene 
expression pattern when compared to PSAB-DCs — and with 
iDCs. Genes upregulated by PS-liposomes, such as CYTH4 and 
TNFSF14, tended to be downregulated in mDCs; other genes 
tended to be differentially expressed in mDCs (NFKBIA, PLAUR, 
TNFAIP3, GIMAP4, VEGFA, and HPGD) in comparison to the 
other conditions.
DiscUssiOn
Apoptosis is a key factor in the maintenance of immunological 
tolerance. The uptake of apoptotic cells, through a process called 
efferocytosis, results in tolerogenic presentation of autoantigens 
inducing specific tolerance rather than autoimmunity (14). 
FigUre 6 | Quantitative RT-PCR validates the RNA-seq results. Relative gene expression of 8 selected targets in immature dendritic cells (iDCs), after phagocytosis 
of PSA-liposomes and PSB-liposomes (PSAB-DCs), and in mature dendritic cells (mDCs), analyzed by quantitative RT-PCR. Gene expression signals were 
normalized to GAPDH. Bars show the mean ± SD of gene expression in control subjects (white bars, n ≥ 3) and patients with type 1 diabetes (T1D) (black bars, 
n ≥ 4). Statistically significant differences were found when comparing the different conditions in the same group of subjects (*p < 0.05, Wilcoxon test), and 
differences were not found when comparing the same culture conditions between patients with T1D and control subjects (Mann–Whitney test).
Table 5 | DEGs in dendritic cells (DCs) from patients with type 1 diabetes (T1D) after PSA-liposomes and PSB-liposomes phagocytosis.
category number  
of Degs
P value representative downregulated genes representative 
upregulated genes
Adhesion 3 ≤0.001076 SCYL3, MEGF9 IGSF9
Antigen processing and 
presentation
7 ≤0.001024 KBTBD6, BTK, CDC23, UBE2E3, CD1D, CUL3, KIF11
Apoptosis 6 ≤0.000593 BLCAP, PMP22, LMNB1, CASP3, DCAF7, BCL2L1
Cell cycle 9 ≤0.001162 CSRP2BP, BUB1, MCPH1, CDK13, PCNA, MCM4, SMC2, NCAPG2, AURKA
Cytokine signaling 9 ≤0.001191 TRIM5, SOCS2, STX3, TNFRSF11A, NUP160 TNFSF14, VEGFA, TNF, 
IFNLR1
Cytoskeleton organization 6 ≤0.000897 MAPRE2, RMDN1, CKAP2, MDM1, RCSD1, CDC42SE1
DNA replication and repair 8 ≤0.000995 WRNIP1, PAXIP1, MSH2, RAD51C, DCLRE1A, ALKBH1, PARG, MLH1
Gene expression 36 ≤0.001293 ZNF436, MYB, ZFP36L2, MIER3, ZBTB5, HHEX, GTF2B, DYRK2, NFIA, ZBTB39
Immunoregulation 25 ≤0.001146 GIMAP4, SLAMF6, DAPP1, MEF2C, BST1, PROS1, MNDA TNFAIP3, PLAUR, NFKBIA
Metabolism 43 ≤0.001225 C9orf64, HPGD, TIMMDC1, ICK, DDO, DCTD, CDYL2, GLRX, TPK1 MFSD2A
Molecule transport 14 ≤0.001252 ERLIN1, SLC10A7, UNC50, ATP10D, SLC40A1, CLCN3, STIM2 SLC43A3, SLCO4A1, 
CLCN6
Post-translational protein 
modification
13 ≤0.001056 FBXO36, NSMCE4A, VWA5A, FBXO25, DCAF12, CBX4, RMND5A, LNX2, 
BTBD3
PPME1
Signal transduction 18 ≤0.001298 SNN, SKI, PAQR8, UBFD1, N4BP1, FZD5, NET1, ZBED3, FRAT2 SHB
Vesicle-mediated processes 8 ≤0.001208 GOLPH3L, SEC22C, RAB32, EHBP1, KIF20B, SNX18 CYTH4, LDLR
DEGs, differentially expressed genes.
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Therefore, the inherent immunomodulatory properties of apop-
totic cells can be useful to design innovative immunotherapies. 
Based on this tolerogenic potential of efferocytosis, we generated 
liposomes that mimic apoptotic β-cells. At present, liposomes are 
clinically used mainly as vehicles for drugs (29–31), but they can 
be designed to modulate immune responses. This liposome-based 
immunotherapy resembles apoptotic cells and acts through the 
immunosuppressive signal of PS (32) and tolerogenic autoantigen 
presentation. These large PS-liposomes, after phagocytosis, are 
effective in restoring self-tolerance in experimental autoimmune 
diseases (16, 17) by their interaction with DCs and the arrest of 
the autoimmune reaction. To explore the clinical potential of this 
strategy, we have determined the effect of PS-liposomes loaded 
with human insulin peptides in DCs from patients with T1D. This 
effect has been assessed in several aspects: phagocytosis, pheno-
typic changes, effect on T cell proliferation and cytokine profile.
Regarding phagocytosis, lipid membrane composition is 
crucial for rapid engulfment by DCs, as demonstrated using PS- 
and PC-liposomes. As expected, the presence of PS accelerated 
phagocytosis of liposomes both in control subjects and patients 
with a dynamic typical of apoptotic cell clearance. PS-liposomes 
were more efficiently engulfed by DCs than the equivalent ones 
without PS in the first 2 h of co-culture, reaching plateau after 
6  h. When encountering PS-liposomes, DCs are deceived into 
sensing that they are actual apoptotic cells that need to be rapidly 
efferocyted in order to avoid secondary necrosis that could con-
tribute to autoimmunity (33, 34). Moreover, the preservation of 
DCs viability proved that PS-liposomes are not toxic, as reported 
for other types of liposomes (29–32).
The second aspect was the assessment of DCs phenotype. 
After liposome engulfment, PSAB-DCs maintained high levels of 
PS-receptors that mediate this uptake, when compared to mDCs, 
pointing to the preservation of phagocytosis ability in tolerogenic 
DCs (tolDCs). Interestingly, the upregulation of TIM4 expres-
sion observed in PSAB-DCs from patients might contribute to a 
positive feedback of phagocytosis. Upon maturation, PS-receptors 
were downmodulated correlating with the phagocytic capacity of 
mDCs, as described (35). The expression pattern of molecules 
involved in antigen presentation (HLA, costimulatory and 
adhesion molecules) in PSAB-DCs concurs with a tolerogenic 
function, both in patients and control subjects. The expression 
of CD25 activation marker, linked to DCs activation and autoim-
munity (36, 37), confirmed the intermediate activation status of 
PSAB-DCs after phagocytosis. Also, the chemokine receptors 
expression pattern supports DCs ability to drive their migra-
tion to secondary lymphoid tissues (38, 39), and moreover, the 
high CCR7 expression is associated with induction of tolerance 
after efferocytosis (40). Additionally, the expression of pattern 
recognition receptors was not altered by liposomes, as described 
for human DCs (32). This phenotype is similar to the previously 
observed in mice (16, 17). Of note, RNA-seq analysis reinforces 
these results. Furthermore, upon liposome capture, the immu-
nomodulatory cytokine TGFβ-1 was secreted, a reported effect 
driven by PS (34) that could suppress DC maturation and define 
the T cell response afterward. As expected, liposome capture did 
not induce IL-6 nor TNF-α secretion by DCs, but maturation did. 
Overall, the results point to the tolerogenic effect of these vesicles, 
which act on re-establishing self-tolerance. We observed minor 
phenotypic differences between DCs from patients and control 
subjects, which could be due to epigenetic changes caused by 
autoimmunity and metabolic dysregulation (41–43).
The third aspect was the analysis of autologous T cell prolifera-
tion induced by PSAB-DCs. In agreement with DCs phenotype, 
T cell proliferation induced by PSAB-DCs was similar or even 
lower than the induced by iDCs, both in patients and control sub-
jects. Interestingly, in patients with T1D, there was a significant 
reduction in CD8+ T cell subset proliferation induced by tolDCs 
when compared to iDCs. This effect could be related to a reduc-
tion of the T cell cytotoxic activity, the most important effector 
response in human T1D (44, 45). In fact, after efferocytosis, 
DCs present apoptotic cell autoantigens to cognate T cells in the 
absence of costimulation, favoring tolerance to self (12, 13). It 
is reasonable to think that liposomes mimicking apoptotic cells 
will cause a similar effect, Additional studies using tetramers 
would be relevant to determine the antigen-specificity of the 
T cells involved in tolerance induction, even in pro-inflammatory 
conditions, in which T cells seem to proliferate more vigorously. 
Cytokines produced during the autologous T  cell proliferation 
assay induced by PSAB-DCs discard a Th1 and Th17 profile, 
which could be detrimental in the induction of tolerance. In fact, 
IFN-γ, which is involved in a Th1 response, and IL-6 secretion, 
which partially contributes to induce Th17 response in T1D (46), 
remain poorly secreted in co-cultures of PBMCs with PSAB-
DCs. Interestingly, higher amounts of IL-6 and IFN-γ tend to 
be produced by mDCs from patients with T1D when compared 
to controls. This feature could reflect the ongoing autoimmune 
reaction, present in peripheral blood from patients (47).
One of the obstacles of tolerogenic therapies in human disease 
is the heterogeneity of the ex vivo-generated tolDCs, which vary 
depending on the source, the manufacturing protocols, and the 
timespan of the experiment. Work is in progress to define and 
standardize a set of phenotypical and functional characteristics of 
tolDCs (48). To date, tolDCs are accepted as maturation-reluctant 
cells with low expression of antigen-presenting and costimula-
tory molecules and a tolerogenic-skewed cytokine profile (49). 
In this sense, one of the advantages of direct administration of 
the liposomes reported herein would be the generation of tolDCs 
in vivo, avoiding ex vivo cell manipulation. Our previous results 
in mice demonstrate this hypothesis (16, 17). However, a global 
picture of changes induced by PS-liposomes phagocytosis would 
grant a better understanding of tolerogenicity.
To fully characterize the immunomodulatory effects of 
liposomes, transcriptomic analysis was performed in DCs. Eight 
patients with a short T1D duration were selected in order to 
minimize the influence of long-term hyperglycemia on immune 
response, as reported (41–43). RNA-seq revealed a set of DEGs 
that avoid DCs maturation and contribute to tolerogenic antigen 
presentation. One of the most hyperexpressed genes was the 
vascular endothelial growth factor (VEGF) A (VEGFA), involved 
in cytokine signaling after efferocytosis (50), iDCs recruitment 
and maturation inhibition (51). VEGF increases the expression 
of the TNFSF14 gene (52), also upregulated by PS-liposomes 
(53). In turn, TNFSF14 upregulates the production of TGF-β by 
phagocytes (54), and upon interacting with its ligand in T cells, 
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TNFSF14 regulates T  cell proliferation (55), inducing local 
immunosuppression (56). Supporting this fact, apoptotic cell 
clearance has been described to inhibit inflammation via TGF-β 
and VEGF production (34). Additionally, VEGFA enhances the 
expression of indoleamine 2,3-dioxygenase (IDO) (57), which 
in turn codifies for an immunomodulatory enzyme expressed 
in tolDCs (58). Moreover, the hematopoietically expressed 
homeobox (HHEX) gene, a repressor of VEGF signaling (59), 
is downregulated after PS-liposomes phagocytosis, whereas an 
inductor of VEGF expression, activating transcription factor 4 
(ATF4) (60), is upregulated. Furthermore, the hyperexpressed 
SH2 domain containing adaptor protein B (SHB) gene codifies 
for a protein that regulates VEGF-dependent cellular migration 
(61), Th2 polarization and T regulatory cell induction (62). Other 
upregulated tolerogenic genes, such as the TNF alpha induced 
protein 3 (TNFAIP3) and the LAIR1, can inhibit DC maturation 
and their deficiency causes autoimmune and autoinflammatory 
diseases (63–66). In the same way, the hyperexpression of the 
NFKBIA gene would contribute to inhibit DC maturation and 
T  cell activation (67, 68). Regarding cytokine signature, our 
results agree with those found in phenotypic and functional 
experiments. A relevant cytokine for tolerance induction is 
TGF-β1, secreted after efferocytosis (69). After PS-liposomes 
capture, DCs showed a biological increase of TGF-β1 tran-
scription, although non-significant, probably due to the short 
timespan of the experiment (70). In fact, TGF-β1 was found in 
culture supernatants 24 h after PS-liposomes phagocytosis. Also, 
the immunoregulatory interferon lambda receptor 1 (IFNLR1) 
gene is one of the few overexpressed in DCs after PS-liposomes 
uptake. This receptor induces tolDCs that promote regulatory 
T cell expansion (71). Unexpectedly, the TNF-encoding gene was 
upregulated in DCs after liposome phagocytosis, and the same 
tendency was observed in protein secretion. Nevertheless, this 
behavior was very different to that observed in mDCs, which 
secreted higher amounts of TNF. The increase of TNF gene 
expression in our RNA-seq agrees with the upregulation of 
TNFSF14 and TNFAIP3 genes. Furthermore, a critical role for 
TNF has been reported in human tolDCs in the induction of 
antigen-specific regulatory T cells (72). Also, our previous results 
showed that murine tolDCs upregulated TNF-gene expression 
after efferocytosis (14). Overall, these results are consistent with 
the pleiotropic effects of TNF. Furthermore, in our previous 
research, PGE2 was found to be crucial in tolerance induced by 
PS-liposomes in mice (16). Strikingly, this pathway does not seem 
to be upregulated in human DCs, probably due to divergences 
between mice and men. Nevertheless, our data indirectly point 
to the involvement of the PGE2 pathway in human DCs: first, 
the downregulation of the hydroxyprostaglandin dehydrogenase 
15-(NAD) (HPGD) gene, involved in PGE2 degradation, and 
second, a biological upregulation (although non-significant) of 
the peroxisome proliferator activated receptor gamma (PPARG), 
a gene induced by prostaglandins which is a negative regulator 
of pro-inflammatory cytokines (73). Furthermore, PGE2 has 
been described to stimulate the synthesis of VEGF (74). In 
summary, comparative transcriptome studies identify the whole 
molecular features of tolDCs rather than describe a simple state 
of maturation or lack thereof in terms of phenotype and function 
(75). Further studies are required to find a common signature 
of tolerogenicity, a fact hindered by individual differences of 
human DCs and the heterogeneous results obtained with dif-
ferent agents used to promote tolDCs. Our findings describe the 
specific gene signature of PS-liposomes-induced tolDCs. Their 
genomic program, which drives a different functionality than 
those of iDCs and mDCs, contributes to dissect the complexity 
of tolerance regulation.
Perhaps not so peculiarly, most of the alterations found in DCs 
after PS-liposomes capture are also physiopathological strategies 
used by tumor cells to escape immune surveillance. Small vesicles 
rich in PS are released by tumor cells and act as immunosuppres-
sive agents to inhibit tumor antigen-specific T cells (76). Tumor 
cells can induce immunological tolerance using mechanisms 
characteristic of apoptotic cell clearance, and PS-liposomes seem 
to make use of the same pathways to achieve similar effects.
The use of PS-liposomes filled with autoantigens is an innova-
tive strategy to arrest autoimmunity by restoring tolerance to self. 
As a whole, our results support the tolerogenic behavior of DCs, 
induced by the phagocytosis of PS-liposomes, and suggest that, 
in the context of autoimmunity, they could act silencing potential 
autoreactive T  cells. This process could possibly be an active 
silencer, and not only a lack of maturation of DCs. In summary, 
here we unveil a picture of efferocytosis mimicry that leads to 
phenotypic and functional changes in human DCs, accountable 
for tolerance induction. The herein reported results reinforce the 
potential of this biocompatible immunotherapy to re-establish 
immunological tolerance, opening the door to new therapeutic 
approaches in the field of antigen-specific autoimmune disorders.
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